Transcatheter Aortic Valve Replacement for Severe Aortic Valve Disease: Multi-center, Real-word Registry
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- all-cause death during follow-up
研究概览
简要总结
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of severe aortic stenosis or aortic regurgitation
- •Patients undergo transcatheter aortic valve replacement
排除标准
- •patients refuse the clinical follow-up
结局指标
主要结局
all-cause death during follow-up
时间窗: 5 years
all-cause death during 5-year follow-up
次要结局
- cardiac death during follow-up(5 years)
研究者
Junjie Zhang
Vice chief
Nanjing First Hospital, Nanjing Medical University
